Benralizumab: A unique IL-5 inhibitor for severe asthma

Laren D. Tan, Jennifer M. Bratt, Dorottya Godor, Samuel Louie, Nicholas Kenyon

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%-10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%-60% of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalJournal of Asthma and Allergy
Volume9
DOIs
StatePublished - Apr 4 2016

Fingerprint

Interleukin-5
Asthma
Inflammation
Eosinophilia
Therapeutics
Glucocorticoids
benralizumab
Antibodies
Population

Keywords

  • Asthma
  • Asthma treatments
  • Benralizumab
  • Eosinophils
  • IL-5
  • IL-5Rα
  • MEDI-563

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Benralizumab : A unique IL-5 inhibitor for severe asthma. / Tan, Laren D.; Bratt, Jennifer M.; Godor, Dorottya; Louie, Samuel; Kenyon, Nicholas.

In: Journal of Asthma and Allergy, Vol. 9, 04.04.2016, p. 71-81.

Research output: Contribution to journalReview article

Tan, Laren D. ; Bratt, Jennifer M. ; Godor, Dorottya ; Louie, Samuel ; Kenyon, Nicholas. / Benralizumab : A unique IL-5 inhibitor for severe asthma. In: Journal of Asthma and Allergy. 2016 ; Vol. 9. pp. 71-81.
@article{1a120e26ef8a450d93fc42475367fc95,
title = "Benralizumab: A unique IL-5 inhibitor for severe asthma",
abstract = "The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5{\%}-10{\%} of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40{\%}-60{\%} of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy.",
keywords = "Asthma, Asthma treatments, Benralizumab, Eosinophils, IL-5, IL-5Rα, MEDI-563",
author = "Tan, {Laren D.} and Bratt, {Jennifer M.} and Dorottya Godor and Samuel Louie and Nicholas Kenyon",
year = "2016",
month = "4",
day = "4",
doi = "10.2147/JAA.S78049",
language = "English (US)",
volume = "9",
pages = "71--81",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Benralizumab

T2 - A unique IL-5 inhibitor for severe asthma

AU - Tan, Laren D.

AU - Bratt, Jennifer M.

AU - Godor, Dorottya

AU - Louie, Samuel

AU - Kenyon, Nicholas

PY - 2016/4/4

Y1 - 2016/4/4

N2 - The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%-10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%-60% of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy.

AB - The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%-10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic airway inflammation represent approximately 40%-60% of this severe asthmatic population. This form of asthma is often uncontrolled, marked by refractoriness to standard therapy, and shows persistent airway eosinophilia despite glucocorticoid therapy. This paper reviews personalized novel therapies, more specifically benralizumab, a humanized anti-IL-5Rα antibody, while also being the first to provide an algorithm for potential candidates who may benefit from anti-IL-5Rα therapy.

KW - Asthma

KW - Asthma treatments

KW - Benralizumab

KW - Eosinophils

KW - IL-5

KW - IL-5Rα

KW - MEDI-563

UR - http://www.scopus.com/inward/record.url?scp=84962727379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962727379&partnerID=8YFLogxK

U2 - 10.2147/JAA.S78049

DO - 10.2147/JAA.S78049

M3 - Review article

AN - SCOPUS:84962727379

VL - 9

SP - 71

EP - 81

JO - Journal of Asthma and Allergy

JF - Journal of Asthma and Allergy

SN - 1178-6965

ER -